PFE vs VST: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and Vistra Corp. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-19.
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
VS
Vistra Corp. · Utilities
$140.67
-23.0% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
PFE has more upside to fair value
(+12.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
VST |
| Current Price |
$27.64 |
$140.67 |
| Fair Value Estimate |
$30.94 |
$108.27 |
| Upside to Fair Value |
+12.0%
|
-23.0%
|
| Market Cap |
$157.5B |
$47.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
17.4x
|
10.3x
|
| Price / Sales |
2.5x
|
3.0x
|
| Price / FCF |
14.3x
|
34.7x
|
| Revenue Growth YoY |
+2.6%
|
-5.5%
|
| Gross Margin |
71.3%
|
13.0%
|
| Operating Margin |
25.1%
|
2.3%
|
| Return on Equity |
4.9%
|
41.5%
|
| Dividend Yield |
6.22% |
0.65% |
| FCF Yield |
6.97%
|
2.88%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Vistra Corp. is a vertically integrated independent power producer and retail electricity supplier operating roughly 38,700 megawatts of generation across natural gas, nuclear, coal, solar, and battery storage, serving about 4.3 million retail customers in 20 states and the District of Columbia. The business quality is mixed: the diversified PJM and ERCOT fleet plus retail load is a genuine struc…
Accumulation Zones
| Metric |
PFE |
VST |
| Zone Low |
$23.21 |
$81.20 |
| Zone High |
$26.30 |
$92.03 |
| In Buy Zone? |
No
|
No
|